BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Return
64.18%
This Quarter Return
+19.22%
1 Year Return
+64.18%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$285M
AUM Growth
+$60.8M
(+27%)
Cap. Flow
+$44.3M
Cap. Flow
% of AUM
15.54%
Top 10 Holdings %
Top 10 Hldgs %
55.03%
Holding
34
New
11
Increased
9
Reduced
1
Closed
13
Top Buys
| 1 |
ENDP
Endo International plc
ENDP
|
+$15.7M |
| 2 |
Alkermes
ALKS
|
+$14.3M |
| 3 |
AKRX
Akorn, Inc.
AKRX
|
+$14.3M |
| 4 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$13.4M |
| 5 |
United Therapeutics
UTHR
|
+$12.9M |
Top Sells
| 1 |
Perrigo
PRGO
|
+$12.5M |
| 2 |
Smith & Nephew
SNN
|
+$12.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$11.1M |
| 4 |
Biogen
BIIB
|
+$11M |
| 5 |
Molina Healthcare
MOH
|
+$9.64M |
Sector Composition
| 1 | Healthcare | 83.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $18.1M | 6.36% |
110,000
+10,000
| +10% | +$1.65M |
|
2
Centene
CNC
$16.3B
| $17.7M | 6.2% |
500,000
+40,000
| +9% | +$1.41M |
|
|
MNK
3
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $16.5M | 5.78% |
130,000
+30,000
| +30% | +$3.8M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $16.2M | 5.67% |
67,500
+20,000
| +42% | +$4.79M |
|
5
Viatris
VTRS
$11.6B
| $16M | 5.62% |
270,000
+75,000
| +38% | +$4.45M |
|
|
ENDP
6
DELISTED
Endo International plc
ENDP
| $15.7M | 5.51% |
+175,000
| New | +$15.7M |
|
|
7
Alkermes
ALKS
$4.45B
| $14.3M | 5.03% |
+235,000
| New | +$14.3M |
|
|
AKRX
8
DELISTED
Akorn, Inc.
AKRX
| $14.3M | 5% |
+300,000
| New | +$14.3M |
|
9
Edwards Lifesciences
EW
$45.5B
| $14.2M | 5% |
600,000
+240,000
| +67% | +$5.7M |
|
10
Intuitive Surgical
ISRG
$161B
| $13.9M | 4.87% |
247,500
+130,500
| +112% | +$7.32M |
|
|
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
| $13.4M | 4.69% |
+285,000
| New | +$13.4M |
|
|
12
United Therapeutics
UTHR
$18.3B
| $12.9M | 4.54% |
+75,000
| New | +$12.9M |
|
13
Teva Pharmaceuticals
TEVA
$22.9B
| $12.8M | 4.48% |
205,000
+25,000
| +14% | +$1.56M |
|
14
Vertex Pharmaceuticals
VRTX
$101B
| $12.4M | 4.35% |
105,000
+37,500
| +56% | +$4.42M |
|
|
CPHD
15
DELISTED
Cepheid Inc
CPHD
| $11.4M | 3.99% |
+200,000
| New | +$11.4M |
|
16
Cooper Companies
COO
$13.3B
| $11.2M | 3.95% |
240,000
-60,000
| -20% | -$2.81M |
|
17
Jazz Pharmaceuticals
JAZZ
$7.65B
| $11.2M | 3.94% |
+65,000
| New | +$11.2M |
|
18
Elevance Health
ELV
$70.2B
| $11.2M | 3.93% |
+72,500
| New | +$11.2M |
|
|
ALR
19
DELISTED
Alere Inc
ALR
| $11M | 3.86% |
+225,000
| New | +$11M |
|
20
BioMarin Pharmaceuticals
BMRN
$10.4B
| $10.9M | 3.83% |
+87,500
| New | +$10.9M |
|
|
ESRX
21
DELISTED
Express Scripts Holding Company
ESRX
| $9.76M | 3.42% |
+112,500
| New | +$9.76M |
|
|
22
Biogen
BIIB
$21.2B
| – | – |
-32,500
| Closed | -$11M |
|
23
Globus Medical
GMED
$7.93B
| – | – |
-275,000
| Closed | -$6.54M |
|
24
Humana
HUM
$33.2B
| – | – |
-62,500
| Closed | -$8.98M |
|
|
25
Molina Healthcare
MOH
$9.8B
| – | – |
-180,000
| Closed | -$9.64M |
|